Literature DB >> 12366662

FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival.

S Memarzadeh1, C H Holschneider, R E Bristow, N L Jones, Y S Fu, B Y Karlan, J S Berek, R Farias-Eisner.   

Abstract

The objective of this study was to assess the impact of surgical cytoreduction on the survival of patients with uterine papillary serous carcinoma (UPSC). Patients added to the institutional tumor registries between January 1980 and September 2001 with the diagnosis of UPSC were reviewed. The records of 43 patients who underwent surgical cytoreduction for FIGO stage III and IV disease were reviewed. The median survival of UPSC patients with microscopic residual disease was significantly improved compared to those with macroscopic residual disease following primary surgical cytoreduction. We conclude that primary surgical cytoreduction resulting in microscopic residual disease is associated with an improvement in recurrence-free survival and overall survival in women with UPSC.

Entities:  

Mesh:

Year:  2002        PMID: 12366662     DOI: 10.1046/j.1525-1438.2002.01149.x

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  10 in total

1.  Debulking Surgery for High-grade Serous Endometrial Cancer with Disseminated Peritoneal Lesions.

Authors:  Nicolae Bacalbasa; Irina Balescu; Alexandru Filipescu
Journal:  In Vivo       Date:  2017 Jul-Aug       Impact factor: 2.155

2.  Factors prognostic of survival in advanced-stage uterine serous carcinoma.

Authors:  Laura L Holman; Navdeep Pal; David A Iglesias; Pamela T Soliman; Nyla Balakrishnan; Ann Klopp; Russell R Broaddus; Nicole D Fleming; Mark F Munsell; Karen H Lu; Shannon N Westin
Journal:  Gynecol Oncol       Date:  2017-04-30       Impact factor: 5.482

3.  Characterization of precursor lesions in the endometrium and fallopian tube epithelium of early-stage uterine serous carcinoma.

Authors:  Mary C Tolcher; Elizabeth M Swisher; Fabiola Medeiros; Joema F Lima; Jodi L Hilderbrand; Janis L Donovan; Rochelle L Garcia; William A Cliby; Sean C Dowdy
Journal:  Int J Gynecol Pathol       Date:  2015-01       Impact factor: 2.762

4.  Clinical implications of neoadjuvant chemotherapy in advanced endometrial cancer: a multi-center retrospective cohort study.

Authors:  Hyunji Lim; Seung Hyun Bang; Yeorae Kim; Sang Hyun Cho; Wonkyo Shin; Se Ik Kim; Tae Hun Kim; Dong Hoon Suh; Myong Cheol Lim; Jae-Weon Kim
Journal:  BMC Cancer       Date:  2022-06-27       Impact factor: 4.638

5.  TLR2 enhances ovarian cancer stem cell self-renewal and promotes tumor repair and recurrence.

Authors:  Ilana Chefetz; Ayesha B Alvero; Jennie C Holmberg; Noah Lebowitz; Vinicius Craveiro; Yang Yang-Hartwich; Gang Yin; Lisa Squillace; Marta Gurrea Soteras; Paulomi Aldo; Gil Mor
Journal:  Cell Cycle       Date:  2013-01-16       Impact factor: 4.534

6.  Surgical management and postoperative treatment of endometrial carcinoma.

Authors:  Jason A Lachance; Christopher J Darus; Laurel W Rice
Journal:  Rev Obstet Gynecol       Date:  2008

7.  Primary cytoreductive surgery for advanced stage endometrial cancer: a systematic review and meta-analysis.

Authors:  Benjamin B Albright; Karen A Monuszko; Samantha J Kaplan; Brittany A Davidson; Haley A Moss; Allan B Huang; Alexander Melamed; Jason D Wright; Laura J Havrilesky; Rebecca A Previs
Journal:  Am J Obstet Gynecol       Date:  2021-05-04       Impact factor: 10.693

8.  Neoadjuvant chemotherapy followed by interval debulking surgery in patients with serous endometrial cancer with transperitoneal spread (stage IV): a new preferred treatment?

Authors:  I Vandenput; B Van Calster; A Capoen; K Leunen; P Berteloot; P Neven; Ph Moerman; I Vergote; F Amant
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

9.  Clinicopathologic study in uterine cancer.

Authors:  I Vandenput
Journal:  Facts Views Vis Obgyn       Date:  2011

10.  Chemotherapy alone may have equivalent survival as compared to suboptimal surgery in advanced endometrial cancer patients.

Authors:  Lisa Rauh; Jeanine N Staples; Linda R Duska
Journal:  Gynecol Oncol Rep       Date:  2020-01-17
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.